NO20052362L - Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner - Google Patents

Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner

Info

Publication number
NO20052362L
NO20052362L NO20052362A NO20052362A NO20052362L NO 20052362 L NO20052362 L NO 20052362L NO 20052362 A NO20052362 A NO 20052362A NO 20052362 A NO20052362 A NO 20052362A NO 20052362 L NO20052362 L NO 20052362L
Authority
NO
Norway
Prior art keywords
dalbavancin
methods
treatment
bacterial infections
administering
Prior art date
Application number
NO20052362A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052362D0 (no
Inventor
Adriano Malabarba
Marco Cavaleri
Giorgio Mosconi
Daniela Jabes
Martin Stogniew
Timothy Henkel
Richard J White
Original Assignee
Vicuron Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32330046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052362(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vicuron Pharm Inc filed Critical Vicuron Pharm Inc
Publication of NO20052362D0 publication Critical patent/NO20052362D0/no
Publication of NO20052362L publication Critical patent/NO20052362L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NO20052362A 2002-11-18 2005-05-12 Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner NO20052362L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42765402P 2002-11-18 2002-11-18
US48569403P 2003-07-08 2003-07-08
US49504803P 2003-08-13 2003-08-13
US49648303P 2003-08-19 2003-08-19
PCT/US2003/036127 WO2004045636A1 (en) 2002-11-18 2003-11-14 Methods of administering dalbavancin for treatment of bacterial infections

Publications (2)

Publication Number Publication Date
NO20052362D0 NO20052362D0 (no) 2005-05-12
NO20052362L true NO20052362L (no) 2005-08-17

Family

ID=32330046

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052362A NO20052362L (no) 2002-11-18 2005-05-12 Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner

Country Status (14)

Country Link
US (12) US20050130909A1 (de)
EP (1) EP1565201B1 (de)
JP (3) JP5519090B2 (de)
KR (2) KR20120056310A (de)
AU (3) AU2003294262B2 (de)
CA (1) CA2506236C (de)
DK (1) DK1565201T3 (de)
ES (1) ES2712656T3 (de)
HU (1) HUE041133T2 (de)
IL (3) IL168327A (de)
MX (1) MXPA05005338A (de)
NO (1) NO20052362L (de)
PT (1) PT1565201T (de)
WO (3) WO2004045637A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO345529B1 (no) * 2004-04-27 2021-03-29 Vicuron Pharm Inc Dalbavancin-materialer for behandling av bakterielle infeksjoner

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1565201B1 (de) * 2002-11-18 2018-10-31 Vicuron Pharmaceuticals, Inc. Methoden zur verabreichung von dalbavancin zur behandung bakterieller infektionen
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20090062182A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched dalbavancin
US8389583B2 (en) * 2008-05-23 2013-03-05 Zurex Pharma, Inc. Antimicrobial compositions and methods of use
US20110132607A1 (en) * 2009-12-07 2011-06-09 Schlumberger Technology Corporation Apparatus and Technique to Communicate With a Tubing-Conveyed Perforating Gun
WO2014152332A1 (en) 2013-03-15 2014-09-25 Melinta Therapeutics, Inc. Methods of treating infections in overweight and obese patients using antibiotics
US10533680B2 (en) 2013-12-19 2020-01-14 Ge Healthcare Bio-Sciences Ab Remotely actuated valve for a biological liquid treatment system
MX385925B (es) 2014-07-17 2025-03-18 The Medicines Co Oritavancina de alta pureza y método para producir la misma.
WO2016071495A1 (en) 2014-11-06 2016-05-12 Xellia Pharmaceuticals Aps Glycopeptide compositions
HK1247283A1 (zh) * 2015-03-02 2018-09-21 科罗纳里康赛普茨有限责任公司 用於peg代谢物及peg分解产物检测的化合物及方法
MX388753B (es) 2015-05-08 2025-03-20 Spectral Platforms Inc Complejos no covalentes basados en albúmina y métodos de uso de los mismos.
WO2017179003A1 (en) 2016-04-15 2017-10-19 Lupin Limited Topical compositions for ophthalmic and otic use
MX2019011119A (es) 2017-03-20 2019-12-19 Spectral Platforms Inc Metodos espectroscopicos para detectar y caracterizar microorganismos.
RU2020104587A (ru) * 2017-07-10 2021-08-10 Контрафект Корпорейшн Потенцирование компонентами крови антибактериальной активности литических белков, соответствующие способы и применения
CN110183519B (zh) * 2019-05-06 2023-04-11 大邦(湖南)生物制药有限公司 一种达巴万星关键中间体a40926的分离纯化方法
CN112480214B (zh) * 2020-12-14 2023-03-28 成都雅途生物技术有限公司 一种达巴万星关键中间体a40926的制备方法
EP4014965A1 (de) 2020-12-16 2022-06-22 EVER Valinject GmbH Wässrige lösung
US20240083950A1 (en) 2021-01-11 2024-03-14 Xellia Pharmaceuticals Aps Synthesis process
CN115215926A (zh) * 2022-08-12 2022-10-21 丽珠集团福州福兴医药有限公司 达巴万星母核及其纯化方法、达巴万星及其合成方法
UY40482A (es) * 2022-10-12 2024-04-30 Hikma Pharmaceuticals Usa Inc Composición líquida de dalbavancina.
AU2023359653A1 (en) * 2022-10-12 2025-05-29 Hikma Pharmaceuticals Usa Inc. Liquid dalbavancin composition
EP4431083A1 (de) 2023-03-16 2024-09-18 Adalvo Limited Formulierung von dalbavancin
EP4431084A1 (de) 2023-03-16 2024-09-18 Adalvo Limited Formulierung von dalbavancin
WO2025158262A1 (en) 2024-01-23 2025-07-31 Lupin Limited Stable pharmaceutical compositions of dalbavancin as ready-to-dilute formulation
GB202405996D0 (en) * 2024-04-29 2024-06-12 Arecor Ltd Novel compositions

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US541616A (en) * 1895-06-25 Elevator attachment
US573679A (en) * 1896-12-22 Apparatus for mowing hay
GB1496386A (en) * 1975-03-05 1977-12-30 Lepetit Spa Antibiotics
US4195079A (en) * 1979-01-31 1980-03-25 Pfizer Inc. New polycyclic ether antibiotic
CA1183789A (en) 1981-08-04 1985-03-12 Kiyoshi Isono Antibiotic 76-11, process for the production thereof, anticoccidiosis agent and domestic animals growth accelerator comprising the same as an effective ingredient
US4578271A (en) 1982-05-24 1986-03-25 Fujisawa Pharmaceutical Co., Ltd. Biologically active WS 6049 substances, a process for the production thereof and their pharmaceutical compositions
FI73697C (fi) 1982-06-08 1987-11-09 Lepetit Spa Foerfarande foer framstaellning av individuella faktorer 1, 2, 3, 4 och 5 av teikomysin a2.
FR2548021B1 (fr) 1983-06-29 1986-02-28 Dick P R Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
GB8415092D0 (en) * 1984-06-13 1984-07-18 Lepetit Spa Ester derivatives
GB8425685D0 (en) 1984-10-11 1984-11-14 Lepetit Spa Antibiotic a 40926 complex
GB8428619D0 (en) * 1984-11-13 1984-12-19 Lepetit Spa Derivatives of antibiotic l 17046
US4914187A (en) * 1984-11-13 1990-04-03 Gruppo Lepetit S.P.A Ester derivatives of antibiotic L 17046
GB8512795D0 (en) 1985-05-21 1985-06-26 Lepetit Spa Increasing ratio of components of teicoplanin a2 complex
GB8531846D0 (en) * 1985-12-30 1986-02-05 Lepetit Spa Antibiotic a 40926 mannosyl aglycon
GB8608809D0 (en) 1986-04-11 1986-05-14 Lepetit Spa Antibiotic
GB8621912D0 (en) 1986-09-11 1986-10-15 Lepetit Spa Increasing ratio of components of anti-biotic complex
GB8621911D0 (en) * 1986-09-11 1986-10-15 Lepetit Spa Increasing ratio of components of anti-biotic complex
GR871488B (en) 1986-10-10 1987-11-12 Lepetit Spa New antibiotics
GB8715735D0 (en) * 1987-07-03 1987-08-12 Lepetit Spa De-mannosyl teicoplanin derivatives
US4882313A (en) * 1987-07-31 1989-11-21 Smithkline Beckman Corporation Carboxamide derivatives of glycopeptides
GB8726859D0 (en) 1987-11-17 1987-12-23 Lepetit Spa 22-dechlorotei-coplanins
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
FR2628269B1 (fr) * 1988-03-04 1990-07-27 Sgs Thomson Microelectronics Dispositif de demarrage progressif d'une alimentation a decoupage
DE68925806T2 (de) 1988-12-27 1996-09-26 Lepetit Spa C63-Amidderivate von 34-de(acetylglucosaminyl)-34-deoxy-teicoplaninen
IE64155B1 (en) 1989-03-29 1995-07-12 Lepetit Spa New substituted alkylamide derivatives of teicoplanin
JPH03193735A (ja) * 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
US5030619A (en) * 1990-04-16 1991-07-09 Miles Inc. Synergistic fungicidal composition
US5606036A (en) * 1991-03-27 1997-02-25 Gruppo Lepetit Spa Antibiotic A 40926 ester derivatives
JP2783722B2 (ja) * 1991-07-12 1998-08-06 麒麟麦酒株式会社 スピカマイシン誘導体およびそれを含む抗腫瘍剤
US5750509A (en) * 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
DK0596929T3 (da) 1991-07-29 1995-09-11 Lepetit Spa Amidderivater af antibiotikum A 40926
US6384013B1 (en) * 1992-03-19 2002-05-07 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US5882900A (en) * 1992-09-10 1999-03-16 Gruppo Lepetit S.P.A. Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium
CA2112776C (en) * 1993-01-21 2002-11-12 Masakazu Tsuchiya Process for inhibiting activity of endotoxin
DE69429617T2 (de) * 1993-04-30 2002-08-22 Biognostik Gesellschaft Fuer Biomolekulare Diagnostik Mbh Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)
SI9500039B (sl) * 1995-02-07 2002-02-28 Lek, Nov kombiniran postopek čiščenja Vankomicin hidroklorida
ATE165101T1 (de) * 1995-02-07 1998-05-15 Biosearch Italia Spa Basische prolinamid derivate von ge2270 und ge2270-ahnlichten antibiotika
JP3518606B2 (ja) * 1995-02-07 2004-04-12 バイオサーチ・イタリア・ソチエタ・ペル・アチオニ Ｇｅ２２７０及びｇｅ２２７０−様抗生物質の塩基性オキサゾリン−アミド誘導体
US5789308A (en) * 1995-06-06 1998-08-04 Advanced Micro Devices, Inc. Manufacturing method for wafer slice starting material to optimize extrinsic gettering during semiconductor fabrication
CA2180206A1 (en) * 1995-06-30 1996-12-31 Motoya Ohshika Freeze-dried preparation for pharmaceutical use
AU701463B2 (en) * 1995-07-05 1999-01-28 Sanofi Aventis S.P.A. Purification of dalbaheptide antibiotics by isoelectric focusing
DE19600590A1 (de) * 1996-01-10 1997-07-24 Tzn Forschung & Entwicklung Schutzvorrichtung für optische Systeme zur Vermeidung von Schäden bei Bestrahlung dieser Systeme mit Laserlicht
EP0880541B1 (de) * 1996-02-14 2003-01-15 Biosearch Italia S.p.A. Derivate des antibiotisch wirkenden faktors ge2270
WO1997038702A1 (en) 1996-04-12 1997-10-23 Eli Lilly And Company Covalently-linked glycopeptide dimers
DK0912604T3 (da) * 1996-04-23 2002-03-25 Biosearch Italia Spa Forbedret kemisk fremgangsmåde til fremstilling af amidderivater af A 40926 antibiotikum
US5935238A (en) * 1997-06-19 1999-08-10 Sun Microsystems, Inc. Selection from multiple fetch addresses generated concurrently including predicted and actual target by control-flow instructions in current and previous instruction bundles
JP4204655B2 (ja) * 1997-08-08 2009-01-07 株式会社ルネサステクノロジ パルス出力機能付マイクロコンピュータ
EP0931834A3 (de) 1997-12-23 2002-06-26 Eli Lilly And Company Echinocandin-bindungsdomäne von 1,3-Beta-glukan Synthase
US6541616B1 (en) * 1998-10-01 2003-04-01 Antex Biologics Inc. Moraxella catarrhalis protein, gene sequence and uses thereof
US6417180B1 (en) 1998-10-07 2002-07-09 University Of Massachusetts Zinc finger-reactive antimicrobial compounds
US6392012B1 (en) * 1998-12-23 2002-05-21 Advanced Medicine, Inc. Glycopeptide derivatives and pharmaceutical compositions containing the same
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
WO2001083520A2 (en) 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
WO2003070756A2 (de) 2002-02-18 2003-08-28 Combinature Biopharm Ag Neue glycopeptid-antibiotika und verfahren zu deren synthetisierung
EP1565201B1 (de) 2002-11-18 2018-10-31 Vicuron Pharmaceuticals, Inc. Methoden zur verabreichung von dalbavancin zur behandung bakterieller infektionen
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO345529B1 (no) * 2004-04-27 2021-03-29 Vicuron Pharm Inc Dalbavancin-materialer for behandling av bakterielle infeksjoner

Also Published As

Publication number Publication date
EP1565201B1 (de) 2018-10-31
HK1114014A1 (en) 2008-10-24
US20050090433A1 (en) 2005-04-28
US20040220122A1 (en) 2004-11-04
AU2003294262B2 (en) 2007-08-23
EP1565201A1 (de) 2005-08-24
US6900175B2 (en) 2005-05-31
AU2003298662A1 (en) 2004-06-15
US20040224908A1 (en) 2004-11-11
AU2003299561A1 (en) 2004-06-15
CA2506236A1 (en) 2004-06-03
ES2712656T3 (es) 2019-05-14
KR20120056310A (ko) 2012-06-01
PT1565201T (pt) 2019-02-05
WO2004046196A2 (en) 2004-06-03
US20090298748A1 (en) 2009-12-03
HK1083684A1 (en) 2006-07-07
US20050032721A1 (en) 2005-02-10
KR20050094396A (ko) 2005-09-27
DK1565201T3 (en) 2019-02-25
NO20052362D0 (no) 2005-05-12
US20040197415A1 (en) 2004-10-07
KR101173310B1 (ko) 2012-08-10
US20040198715A1 (en) 2004-10-07
IL168327A (en) 2014-02-27
JP2006514092A (ja) 2006-04-27
JP2013155188A (ja) 2013-08-15
AU2003294262A1 (en) 2004-06-15
US20050130909A1 (en) 2005-06-16
JP5519090B2 (ja) 2014-06-11
HUE041133T2 (hu) 2019-05-28
MXPA05005338A (es) 2005-12-14
IL239913A0 (en) 2015-08-31
US7115564B2 (en) 2006-10-03
IL230875A0 (en) 2014-03-31
WO2004046196A3 (en) 2004-08-19
IL239913B (en) 2019-01-31
US20040142883A1 (en) 2004-07-22
WO2004045636A1 (en) 2004-06-03
US20090305953A1 (en) 2009-12-10
US20050004011A1 (en) 2005-01-06
CA2506236C (en) 2018-07-17
US20050130914A1 (en) 2005-06-16
WO2004045637A1 (en) 2004-06-03
JP2011157381A (ja) 2011-08-18

Similar Documents

Publication Publication Date Title
MXPA05005338A (es) Metodos para administrar dalbavancin para el tratamiento de infecciones bacterianas.
NO20064287L (no) Dalbavancin-materialer for behandling av bakterielle infeksjoner
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
EA200600820A1 (ru) Способы лечения, модификации и устранения боли с использованием 1-оксо-2-(2,6-диоксопиперидин-3-ил)-4-метилизоиндолина
WO2002078627A3 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
NO20090887L (no) Fremgangsmate for behandling og forebygging av mukositt
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
BRPI0509140A (pt) processos para o tratamento de infecção por hiv
MX2022009197A (es) Metodos de tratamiento para deficiencia de alfa-1 antitripsina.
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
WO2022053993A3 (en) Treatments for sars-cov-2 infection (covid-19)
TW202617146A (zh) 包含靶向ｖａｖ１的降解劑的組合
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
ATE536178T1 (de) Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis
EP1620061A4 (de) Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
TW200420290A (en) Methods for the treatment, prevention and management of macular degeneration
TW200719903A (en) Compositions for the treatment of neoplasms
EA200801890A1 (ru) Средство для лечения шума в ушах
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
FI20010233A0 (fi) Menetelmä sydämen vajaatoiminnan hoitoon
IL183924A (en) Use of a combination of active agents in the preparation of pharmaceutical compositions
MX2025009380A (es) Polipéptido y sus derivados, composición que comprende los mismos, y uso de los mismos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application